Introduction {#Sec1}
============

The two efficacy studies described in this paper were conducted to evaluate the speed of relief onset from a new aspirin swallowable tablet formulation compared to regular aspirin. Based on the improved dissolution and pharmacokinetic profile, the expectation was that this formulation would have a clinically meaningful advantage in time to onset of pain relief.

Self-treatment of acute mild-to-moderate pain with over-the-counter (OTC) analgesics is well established in the general population. Aspirin (acetylsalicylic acid, ASA) is one of the most commonly used analgesics worldwide for this purpose. Its efficacy has been shown in several acute pain conditions, including tension-type headache (Steiner et al. [@CR22]; Martinez-Martin et al. [@CR21]; MacEachern et al. [@CR19]), migraine headache (MacGregor et al. [@CR20]; Lange et al. [@CR17]; Diener et al. [@CR7], [@CR8], [@CR9]; Lipton et al. [@CR18]; Lampl et al. [@CR16]), sore throat (Eccles et al. [@CR11]), primary dysmenorrhea (Zhang and Li Wan Po [@CR24]) and dental pain (Forbes et al. [@CR14], [@CR15]; Cooper [@CR2], [@CR3]), as well as fever (Bachert et al. [@CR1]).

The key domains recognized by consumers for an efficacious acute analgesic are fast onset, long duration and complete pain relief. Fast onset of action is of particular importance in an outpatient, self-medication environment. Several pain models have been performed to assess pain relief and onset of relief (Cooper [@CR4]); however, the Dental Impaction Pain Model (DIPM) is the most well established. The sensitivity, reproducibility and reliability of this model are well documented (Cooper and Desjardins [@CR5]; Desjardins et al. [@CR6]). The American Food and Drug Administration and the European Medicines Agency both identified the third molar extraction dental pain model as acceptable for assessing analgesia in acute mild-to-moderate pain (Food and Drug Administration [@CR13]; European Medicines Agency [@CR12]).

A novel aspirin formulation with an effervescent component consisting of sodium carbonate and micronized active ingredient has been developed. This new swallowable tablet formulation has been shown to decrease substantially the in vitro dissolution time and in vivo time to maximum plasma concentration The small active ingredient particle size provides a much larger surface area than the Aspirin^®^ regular tablet resulting in faster dissolution and consequently faster in vivo absorption (Voelker [@CR23]).

Two tablet strengths of the new formulation fast release (FR-aspirin) contain either 325 or 500 mg aspirin, resulting in a total dose of either 650 or 1,000 mg. In these two efficacy studies, we investigated whether the pharmaceutical and pharmacokinetic properties were associated with a faster onset of pain relief compared to a corresponding strength of regular Aspirin^®^ 325 mg or 500 mg (R-aspirin).

Methods {#Sec2}
=======

The studies were designed to evaluate the analgesic efficacy of a single, oral dose of FR-aspirin tablets compared to R-aspirin tablets and placebo in subjects with postsurgical pain resulting from the surgical removal of impacted third molars. Patients were required to have one of the following surgical procedures: either two partial bony impacted mandibular third molars, one full bony impacted mandibular third molar, or one partial bony impacted and one fully bony impacted mandibular third molars removed. Additionally, any maxillary third molars could have been removed regardless of impaction level.

Each study was conducted at a single study site. For Study 1, the treatment arms were: placebo, R-aspirin 1,000 mg, FR-aspirin 1,000 mg. For Study 2, the treatment arms were: placebo, R-aspirin 650 mg, FR-aspirin 650 mg. Both were randomized, double-blind, parallel group and single-dose studies. The randomization scheme in both studies was 2:2:1 for the ratio of active drugs to placebo. Because the FR-aspirin and R-aspirin tablets were not identical in appearance, subjects had a blinding device applied and the study drugs were administered by a third party who was not otherwise involved in the conduct of the study. The aspirin comparator was commercially available Aspirin^®^ regular tablet 500 mg or Bayer Aspirin^®^ 325 mg tablets (both Bayer HealthCare, Germany).

Studies were conducted according to the principles of the International Conference on Harmonisation Harmonised Tripartite Guideline E6(R1): Good Clinical Practice (GCP), the World Medical Association Declaration of Helsinki and its most recent amendments, and United States Title 21 of the Code of Federal Regulations Parts 50 and 56 concerning informed consent and IRB regulations. Written informed consent was obtained from each subject at screening before the initiation of any study-related procedures.

Patients were included in the studies if they had moderate or severe postsurgical pain within 1--4 h after surgery and a score of ≥5 on the 11-point numerical pain intensity rating scale (NRS) (0 = no pain to 10 = very painful).

Patients were provided with two stopwatches starting at study drug administration: the first was stopped when they first felt any perceptible pain relief and the second was pressed when they felt pain relief that was in their estimation meaningful. The patients recorded pain intensity (PI) and pain relief (PR) at 10, 20, 30, 40, 50 and 60 min and at 2, 3, 4, 5 and 6 h after dosing. PI was rated on a four-point categorical pain intensity scale (0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain); PR was rated using a five-point categorical pain relief rating scale (0 = no relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, and 4 = complete relief). At the 6-h observation or at the time of rescue analgesic if it occurred prior to the 6th h observation, subjects completed a five-point categorical global evaluation of the study drug (0 = poor, 1 = fair, 2 = good, 3 = very good, and 4 = excellent). Rescue medication was Lortab 5 (hydrocodone 5 mg/acetaminophen 500 mg) tablets. Adverse events were monitored and recorded throughout the dosing period. After completion of the dosing period, the study sites had the option of either contacting subjects within 2--5 days or scheduling subjects for a follow-up office appointment to assess surgical healing, the occurrence or persistence of adverse events and medications taken. The primary efficacy end point was time to first perceptible pain relief. Secondary variables were time to meaningful PR, PI and PI differences, summed pain intensity differences (SPID) and total pain relief (TOTPAR) values at 2, 4 and 6 h and global evaluation.

Statistical analysis {#Sec3}
--------------------

A sample size calculation for each study of approximately 500 subjects (200 subjects per aspirin treatment group and 100 subjects in the placebo group) provided 90% power to detect a treatment difference between FR-aspirin and R-aspirin for time to pain relief at a two-sided significance level of 0.05.

All hypotheses were tested at a two-sided significance level of 0.05. Efficacy variables were analyzed using all randomized subjects who took the study drug and who had at least one post-dose assessment on an efficacy parameter (intent to treat).

Time to first perceptible PR and meaningful PR were plotted using the Kaplan--Meier method and compared between treatment groups using the log-rank test. Median times to first perceptible PR and meaningful PR were calculated and presented.

Time-weighted SPIDs and TOTPARs were calculated for 6 h. An analysis of covariance (ANCOVA) model was used to compare means across treatment groups for the following secondary efficacy end points: SPID~0--2~, SPID~0--4~, SPID~0--6~, TOTPAR~0--2~, TOTPAR~0--4~, TOTPAR~0--6~ and PID at each post-dose time point. The ANCOVA model included treatment and center as the fixed effects and baseline pain as the covariate. In each analysis, adjusted least squares (LS) mean standard error and LS mean difference, along with 95% confidence intervals (CIs) of the difference, were obtained from the model.

Results of Study 1: 500 mg aspirin tablet {#Sec4}
=========================================

Efficacy evaluations were made on the basis of the 514 patients included in the intent-to-treat (ITT) population for Study 1 (500 mg of aspirin). There were no group differences with respect to age, gender and baseline pain intensity (Table [1](#Tab1){ref-type="table"}). The majority of patients were of younger age with a range of means of 22.4--22.7 years for the three treatment groups. At baseline, the overall mean PI score was 6.6 on the 11-point NRS. Approximately, 80% of patients in this study graded their baseline pain as moderate and 20% as severe. Approximately, three-quarters of the patients underwent removal of two impacted mandibular molars with a majority of patients having a total of three molars removed (Table [1](#Tab1){ref-type="table"}).Table 1Summary of demographics and baseline characteristicsStudyVariableAspirin fast-release tabletAspirin regular tabletPlacebo500 mg (Study 1)ITT population206203105Age, \[years (mean + SD)\]22.4 (4.62)22.7 (4.85)22.5 (4.24)Gender ratio, male:female (%)44.7:55.341.9:58.150.5:49.511-point intensity \[mean (SD)\]6.6 (1.14)6.5 (1.07)6.6 (1.17)Categorical pain intensity (%) Moderate80.680.379.0 Severe19.419.721.0Number of molars removed (%) 117.021.217.1 282.078.379.0 31.00.53.8Tooth sites (%)^a^ Left upper third molar35.932.535.2 Left lower third molar43.738.941.0 Right upper third molar46.648.850.5 Right lower third molar57.859.160.0Impaction score (%)^a^ Erupted in tissue23.326.624.8 Broken soft tissue10.213.821.0 Partial bony impaction38.332.529.5 Full bony impaction85.986.785.7325 mg (Study 2)ITT population200200100Age, years \[mean (SD)\]20.3 (3.33)20.8 (4.05)20.7 (3.57)Gender ratio, male:female (%)31.5:68.541.5:58.534.0:66.011-point intensity \[mean (SD)\]7.3 (1.30)7.4 (1.35)7.5 (1.40)Categorical pain intensity (%) Moderate57.055.556.0 Severe43.044.544.0Number of molars removed (%) 16.03.08.0 287.588.088.0 3000 46.59.04.0Tooth sites (%)^a^ Left upper third molar66.059.061.0 Left lower third molar69.065.068.0 Right upper third molar65.566.561.0 Right lower third molar68.573.566.0Impaction score (%)^a^ Erupted in tissue9.08.514.0 Broken soft tissue5.58.58.0 Partial bony impaction45.050.041.0 Full bony impaction84.579.588.0^a^Patients may have had more than one affected tooth site or impaction score

Kaplan--Meier plots of time to first perceptible pain relief and meaningful pain relief showed a statistically significant difference between FR-aspirin tablets and R-aspirin tablets (*p* \< 0.05). Both active treatments were significantly faster than placebo (*p* \< 0.001) (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}; Table [2](#Tab2){ref-type="table"}). Median time to first perceptible pain relief was 16.3 min for FR-aspirin 500 mg and 20.0 min for R-aspirin 500 mg. Median time to meaningful pain relief was 49.4 min for FR-aspirin versus 99.2 min for R-aspirin. A higher percentage of patients in the FR-aspirin group achieved pain relief compared to R-aspirin and placebo (first perceptible pain relief: 92.2 vs. 85.7 vs. 70.5% and meaningful relief: 65.0 vs. 62.1 vs. 37.1%).Fig. 1Kaplan--Meier plot of time to first perceptible and meaningful pain relief from aspirin 500 mgFig. 2Kaplan--Meier plot of time to first perceptible and meaningful pain relief from aspirin 325 mgTable 2Time to relief and efficacy resultsStudyVariableAspirin fast-release tabletAspirin regular tabletPlacebo500 mg (Study 1)Median time to FPR, min (95% CI)16.3 (12.2, 19.2)20.0 (15.7, 23.4)20.0 (18.9. 30.0)*p* value versus fast-release aspirin--0.004\<0.001*p* value versus regular aspirin----0.014% of subjects achieved PR92.285.770.5% of subjects censored7.814.329.5Median time to MR, min (95% CI)49.4 (40.2, 57.7)99.2 (77.0, 148.3)NA (NA, NA)*p* value versus fast-release aspirin--0.038\<0.001*p* value versus regular aspirin----\<0.001% of subjects achieved PR65.062.137.1% of subjects censored35.037.962.9SPID 0--2 h, mean (SD)1.3 (1.5)1.0 (1.5)0.2 (1.3)*p* value versus fast-release aspirin--0.026\<0.001*p* value versus regular aspirin----\<0.001SPID 0--4 h, mean (SD)1.9 (3.2)2.0 (3.4)0.3 (3.2)*p* value versus fast-release aspirin--0.922\<0.001*p* value versus regular aspirin----\<0.001SPID 0--6 h, mean (SD)2.3 (4.7)2.8 (5.3)0.5 (5.2)*p* value versus fast-release aspirin--0.4030.003*p* value versus regular aspirin----\<0.001TOTPAR 0--2 h, mean (SD)3.3 (2.2)2.8 (2.2)1.7 (2.0)*p* value versus fast-release aspirin--0.018\<0.001*p* value versus regular aspirin----\<0.001TOTPAR 0--4 h, mean (SD)5.7 (4.5)5.6 (4.8)3.5 (4.6)*p* value versus fast-release aspirin--0.882\<0.001*p* value versus regular aspirin----\<0.001TOTPAR 0--6 h, mean (SD)7.6 (6.6)8.0 (7.5)5.5 (7.6)*p* value versus fast-release aspirin--0.4630.013*p* value versus regular aspirin----0.002325 mg (Study 2)Median Time to FPR, min (95% CI)19.8 (18.2, 20.0)23.7 (19.2, 30.0)41.4 (30.7 103.9)*p* value versus fast-release aspirin--\<0.001\<0.001*p* value versus regular aspirin----\<0.001% of subjects achieved PR95.085.062.0% of subjects censored5.015.038.0Median time to MR, min (95% CI)48.9 (41.8, 54.5)119.2 (93.6, 192.3)NA (NA, NA)*p* value versus fast-release aspirin--\<0.001\<0.001*p* value versus regular aspirin----\<0.001% of subjects achieved PR72.559.030.0% of subjects censored27.541.070.0SPID 0--2 h, mean (SD)1.7 (1.6)1.2 (1.5)0.1 (1.2)*p* value versus fast-release aspirin--\<0.001\<0.001*p* value versus regular aspirin----\<0.001SPID 0--4 h, mean (SD)2.8 (3.5)2.7 (3.4)0.3 (2.7)*p* value versus fast-release aspirin--0.668\<0.001*p* value versus regular aspirin----\<0.001SPID 0--6 h, mean (SD)3.5 (5.4)3.8 (5.3)0.6 (4.5)*p* value versus fast-release aspirin--0.631\<0.001*p* value versus regular aspirin----\<0.001TOTPAR 0--2 h, mean (SD)3.6 (2.1)2.7 (2.1)1.1 (1.4)*p* value versus fast-release aspirin--\<0.001\<0.001*p* value versus regular aspirin----\<0.001TOTPAR 0--4 h, mean (SD)6.3 (4.8)6.0 (4.8)2.3 (3.4)*p* value versus fast-release aspirin--0.437\<0.001*p* value versus regular aspirin----\<0.001TOTPAR 0--6 h, mean (SD)8.5 (7.4)8.6 (7.4)3.7 (5.7)*p* value versus fast-release aspirin--0.875\<0.001*p* value versus regular aspirin----\<0.001*FPR* first perceptible pain relief, *MR* meaningful relief, *CI* confidence interval, *SPID* summed pain intensity differences, *TOTPAR* total pain relief. *NA* not available

The SPID and TOTPAR results were consistent with the greater efficacy for the FR-aspirin compared to the R-aspirin and placebo. At 2 h, differences between FR-aspirin and R-aspirin were significant \[*p* = 0.026 (SPID) and *p* = 0.018 (TOTPAR)\] and both actives were statistically superior compared with placebo (*p* \< 0.001). For the 4- and 6-h measurements, SPID and TOTPAR for the FR-aspirin and R-aspirin were not different from each other, but both were statistically significantly greater than placebo (Table [2](#Tab2){ref-type="table"}).

With respect to the global evaluation, the majority of subjects treated with FR-aspirin and R-aspirin rated their treatment as "fair" or better; while the majority of subjects treated with placebo rated their treatment as poor. More subjects treated with FR-aspirin assessed as very good or excellent (18.0 and 6.3%) compared with R-aspirin \[13.8 and 5.4% (Table [3](#Tab3){ref-type="table"})\].Table 3Global assessment of treatmentsStudyVariableAspirin fast-release tablet (%)Aspirin regular tablet (%)Placebo (%)500 mg (Study 1)Poor25.731.558.1Fair26.220.713.3Good22.328.119.0Very good18.013.85.7Excellent6.35.42.9325 mg (Study 2)Poor19.529.060.0Fair16.518.517.0Good29.024.016.0Very good22.019.55.0Excellent12.58.00.0

Both active treatments were well tolerated. No serious adverse events were reported and no subject was discontinued due to adverse event in either 500 mg aspirin treatment group.

Results of Study 2: 325 mg aspirin tablet {#Sec5}
=========================================

Efficacy evaluations were made on the basis of the 500 patients included in the intent-to-treat (ITT) population for Study 2 (325 mg aspirin). There were no group differences with respect to age, gender and baseline pain intensity (Table [1](#Tab1){ref-type="table"}). The majority of patients were of younger age with a range of means of 20.3--20.8 years for the three treatment groups. At baseline, the overall mean PI score was 7.4 on the 11-point NRS. Approximately, 57% of patients graded moderate baseline pain and 43% severe baseline pain. Approximately, three-quarters of patients underwent removal of two impacted mandibular molars with a majority of patients having a total of four molars removed (Table [1](#Tab1){ref-type="table"}).

Kaplan--Meier plots of time to first perceptible pain relief and meaningful pain relief showed a statistically significant difference between FR-aspirin tablets and R-aspirin tablets (*p* \< 0.05). Both active treatments were significantly faster than placebo (*p* \< 0.001) (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}; Table [2](#Tab2){ref-type="table"}). Median time to first perceptible pain relief was 19.8 min for FR-aspirin 325 mg and 23.7 min for R-aspirin 325 mg. In this study, median time to meaningful pain relief was 48.9 min for FR-aspirin versus 119.2 min for R-aspirin. A higher percentage of patients in the FR-aspirin group achieved pain relief compared to R-aspirin and placebo (first perceptible pain relief: 95.0 vs. 85.0 vs. 62.0% and meaningful relief: 72.5 vs. 59.0 vs. 30.0%).

The SPID and TOTPAR measurements showed the same consistent pattern as Study 1 for the comparisons between FR-aspirin, R-aspirin and placebo. At 2 h, differences between FR-aspirin and R-aspirin were significant (*p* \< 0.001 SPID and TOTPAR) and both actives were statistically superior compared with placebo (*p* \< 0.001). Similar to Study 1, for the 4- and 6-h SPID and TOTPAR measurements, the aspirin groups were not different; whereas both were statistically significantly greater than placebo (Table [2](#Tab2){ref-type="table"}).

With respect to global evaluation, the majority of subjects treated with FR-aspirin and R-aspirin assessed as "fair" or better; while the majority of subjects treated with placebo assessed as "poor". More subjects treated with FR-aspirin assessed as very good or excellent (22.0 and 12.5%) compared with R-aspirin \[19.5 and 8.9% (Table [3](#Tab3){ref-type="table"})\].

Both active treatments were well tolerated. In this study, there was one aspirin 325 mg subject in the R-aspirin group, who experienced a serious adverse event of gastritis that was considered not related to the study drug, and two subjects (1 in the R-aspirin group and 1 in the placebo group) who discontinued due to non-serious adverse events.

In both studies, the percentages of patients taking rescue medication (1,000 mg study: FR-aspirin = 57.8%, R-aspirin = 49.8%, placebo = 68.6% and 650 mg study: FR-aspirin = 59.0%, R-aspirin = 51.0%, placebo = 72.0%) and the median times to rescue medication (1,000 mg study: FR-aspirin = 252 min, R-aspirin \> 360 min, placebo = 124 min and 650 mg study: FR-aspirin = 268 min, R-aspirin = 322 min, placebo = 105 min) were not statistically significantly different between active treatments, but both actives were significantly better than placebo (*p* \< 0.001).

Safety results {#Sec6}
==============

Adverse events of the individual studies are shown in Table [4](#Tab4){ref-type="table"}. In Study 1, between 15 and 22% of subjects experienced at least one adverse event; in Study 2, between 14 and 18%. Gastrointestinal adverse events appeared between 4 and 8% in Study 1 and between 5 and 8% in Study 2. The most common GI adverse event was nausea.Table 4Treatment emergent adverse events of individual studies with aspirin frequencies \>1% \[number (percentages)\]StudyStudy 1 aspirin 1,000 mgStudy 2 aspirin 650 mgVariableAspirin fast-release tabletAspirin regular tabletPlaceboAspirin fast-release tabletAspirin regular tabletPlaceboTotal number of patients treated206203105200200100Total number of adverse events503636413923Number of subjects with at least one adverse event38 (18.4%)31 (15.3%)23 (21.9%)29 (14.5%)30 (15.0%)18 (18.0%)Gastrointestinal disorders10 (4.9%)8 (3.9%)8 (7.6%)13 (6.5%)10 (5.0%)8 (8.0%)Nausea8 (3.9%)6 (3.0%)5 (4.8%)9 (4.5%)5 (2.5%)6 (6.0%)Vomiting5 (2.4%)1 (0.5%)3 (2.9%)3 (1.5%)2 (1.0%)1 (1.0%)Nervous system disorders12 (5.8%)16 (7.9%)13 (12.4%)5 (2.5%)11 (5.5%)5 (5.0%)Dizziness4 (1.9%)2 (1.0%)2 (1.9%)4 (2.0%)3 (1.5%)3 (3.0%)Headache8 (3.9%)14 (6.9%)9 (8.6%)1 (0.5%)8 (4.0%)1 (1.0%)Infections and infestations13 (6.3%)9 (4.4%)5 (4.8%)9 (4.5%)8 (4.0%)3 (3.0%)Alveolar osteitis12 (5.8%)9 (4.4%)5 (4.8%)6 (3.0%)6 (3.0%)3 (3.0%)

Discussion {#Sec7}
==========

If an analgesic works fast, the consumers get the relief they seek and then there is less likelihood of taking additional medication that can result in unwanted side effects. In the recent past, several OTC analgesics were introduced as softgel or liquigel formulations with the putative advantage of a faster onset of action (Doyle et al. [@CR10]). Interestingly, to our knowledge, none of these analgesics has ever directly compared the new formulation to the original formulation in a double-blinded efficacy study. These drugs rely on dissolution and pharmacokinetic data to justify their putative onset advantage; but this is not necessarily directly correlated into a clinical advantage. In the two studies presented, the efficacy data clearly demonstrate that the new formulation of aspirin has a faster onset of action at both the 650 mg and 1,000 mg doses. For the aspirin 650 mg dose, the median time to meaningful relief was 70.3 min faster than regular aspirin, and for the 1,000 mg aspirin dose, the median time to meaningful relief was 49.8 min faster than regular aspirin. From a clinical standpoint, this is a very relevant advantage and was accomplished without the addition of any active adjuvant such as caffeine. This advanced aspirin formulation was accomplished by incorporating an effervescent component (sodium carbonate) and micronized active ingredient. Unlike a softgel or liquigel formulation, this aspirin formulation retains the advantage of still being a tablet.

Furthermore, the overall efficacy of the FR-aspirin tablet was sustained as shown by the non-significant differences between FR-aspirin and R-aspirin for the SPID- and TOTPAR measurements and the use of rescue medication over the 6-h observation period.

The dental impaction pain model was chosen for these studies because of its proven validity, reliability and sensitivity. The results of these two studies are consistent with previous dental studies and there was a strong correlation between the improved pharmacokinetics of the new aspirin formulation and clinical efficacy.

It can be postulated that the minor outcome differences between the two studies can be explained by the expected variability between the two different study sites. Furthermore, distribution of baseline pain intensity was different in the two studies. However, the results of the two studies were remarkably consistent and supportive of the faster onset for the FR-aspirin formulations.

Conclusions {#Sec8}
===========

The two efficacy studies described in this paper clearly demonstrate that the onset of analgesic efficacy is improved by adding an effervescent component (sodium carbonate) and micronized active ingredient to the aspirin formulation. The enhanced onset did not adversely impact either the peak effect or duration of effect compared to regular aspirin. In addition, the side effect data from these single dose studies did not indicate any change in the side effect profile. The initial findings of significantly improved dissolution and pharmacokinetic profiles for this new rapidly acting aspirin formulation were confirmed in these two well-controlled efficacy studies.

The investigators William L. Buchanan, MD, DDS, PPD Development, Austin, TX, USA and Lynn R. Webster, MD, Lifetreee Clinical Research, Salt Lake City, UT, USA participated in conducting the study with fast-release aspirin500 mg (Study 1). The investigators Patrick R. Brain, DDS, Jean Brown Research, Salt Lake City, UT, USA and Stephen E. Daniels, DO, Premier Research Group, Austin, TX, USA participated in conducting the study with fast-release aspirin 325 mg (Study 2). The two studies were funded by Bayer Consumer Care, Morristown, NJ, USA.
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